

FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE

OFFICIAL

Applicants Docket Number:
USST98032 US PCTApplicants:
BRANELLEC, et al.Serial No.
09/787,995Filing Date:
July 9, 2001Title of Invention:
USE OF SPECIFIC HYBRID PROMOTERS FOR CONTROLLING TISSUE EXPRESSION

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Maria B. Marvich, PhD, at 703-308-4244, on November 24, 2003.

Printed Name of Person Signing Certificate: Jonas Pierre, Sr.Signature: [Signature]

Total Number of Pages Sent: 12

Attorney: F. Aaron Dubberley

Reg. No. 41,001

Group Art Unit: 1636

Examiner: Maria B. MARVICH, PhD

TO: Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of **Aventis Pharmaceuticals Inc.**

- | | |
|--|--|
| <input checked="" type="checkbox"/> Amendment | <input type="checkbox"/> Fee Transmittal |
| <input type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input checked="" type="checkbox"/> Extension of Time Petition | <input type="checkbox"/> Other _____ |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input type="checkbox"/> Other _____ |
| <input type="checkbox"/> Maintenance Fee Transmittal | |

Receipt Confirmed:

Signed _____

Dated _____

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08607 U.S.A. www.aventis.com
NOTICE: This document is accompanying this facsimile transmission and is intended only for the use of the individual or entity named above. If you have received this document in error, please immediately notify the sender by telephone or otherwise for the return of the original documents.

Aventis Pharmaceuticals Inc. (update March 2001)